iX Biopharma (SGX:42C) FCF Margin % : -56.32% (As of Dec. 2024)

View and export this data going back to 2015. Start your Free Trial

What is iX Biopharma FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. iX Biopharma's Free Cash Flow for the six months ended in Dec. 2024 was S$-2.09 Mil. iX Biopharma's Revenue for the six months ended in Dec. 2024 was S$3.71 Mil. Therefore, iX Biopharma's FCF Margin % for the quarter that ended in Dec. 2024 was -56.32%.

As of today, iX Biopharma's current FCF Yield % is -38.22%.

The historical rank and industry rank for iX Biopharma's FCF Margin % or its related term are showing as below:

SGX:42C' s FCF Margin % Range Over the Past 10 Years
Min: -3881.3 Med: -159.38 Max: 20.31
Current: -82.43

During the past 11 years, the highest FCF Margin % of iX Biopharma was 20.31%. The lowest was -3881.30%. And the median was -159.38%.

SGX:42C's FCF Margin % is ranked worse than
90.8% of 967 companies
in the Drug Manufacturers industry
Industry Median: 1.03 vs SGX:42C: -82.43

iX Biopharma FCF Margin % Historical Data

The historical data trend for iX Biopharma's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iX Biopharma FCF Margin % Chart

iX Biopharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

FCF Margin %

Get a 7-Day Free Trial

-945.58

-510.32

20.31

-141.30

-114.75

iX Biopharma Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial															-170.61	-119.41	-118.23	-111.93	-56.32

Competitive Comparison of iX Biopharma's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

iX Biopharma's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's FCF Margin % distribution charts can be found below:

* The bar in red indicates where iX Biopharma's FCF Margin % falls into.

Save Embed

;

Save Embed

;

iX Biopharma FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

iX Biopharma's FCF Margin for the fiscal year that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2024 )	/	Revenue (A: Jun. 2024 )
	=	-6.838	/	5.959
	=	-114.75 %

iX Biopharma's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-2.091	/	3.713
	=	-56.32 %

iX Biopharma FCF Margin % Related Terms

Thank you for viewing the detailed overview of iX Biopharma's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

iX Biopharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » iX Biopharma Ltd (SGX:42C) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Kim Seng Promenade, No. 14-01, Great World City East Lobby, Singapore, SGP, 237994

Website

https://www.ixbiopharma.com

iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.

iX Biopharma Headlines

No Headlines